alexa Attempt to Explore the Binding Mechanism of IL-1ÎÂ
ISSN: 2161-0444

Medicinal Chemistry
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Attempt to Explore the Binding Mechanism of IL-1β Inhibitors via Molecular Docking Studies

Sobia Ahsan Halim1,2* and Muhammad Jawad2

1Department of Biochemistry, Kinnaird College for Women, 93-Jail Road, Lahore, Pakistan

2National Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan

*Corresponding Author:
Sobia Ahsan Halim
Department of Biochemistry
Kinnaird College for Women
93-Jail Road, Lahore, Pakistan
Tel: +92 42 99203781-84 extn. 226
E-mail: [email protected]; [email protected]

Received date: September 29, 2015; Accepted date: October 12, 2015; Published date: October 15, 2015

Citation: Halim SA, Jawad M (2015) Attempt to Explore the Binding Mechanism of IL-1β Inhibitors via Molecular Docking Studies. Med chem 5:452-457. doi:10.4172/2161-0444.1000300

Copyright: © 2015 Halim SA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



IL-1β is an important cytokineinvolved in several immune responses. IL-1β exerts its effect by binding with its receptorcalled IL-1R1 and leading to a series of intra-cellular signalling. The over-expression of IL-1β leads to immunological complications including arthritis and auto-immune disorders. Currently there are several drugs in the market to cure the inflammation either by inhibiting the production of IL-1β or affecting its signal cascade. The hindrance in the interaction between IL-1β interaction and its receptor can stop its function hence hope to cure inflammatory diseases. This study presents a docking analysis of five commercially available drugs at the IL-1β/IL-1R1 protein interface. This study would give an insight for designing the drugs, capable to block the direct interaction of IL-1β with its receptor ultimately leading to some more consistent cure for inflammatory diseases.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version